Nektar Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.01.18	Hyland Healthcare Partners with Jopari to Offer OnBase Mackinac Access (PR Newswire)
27.11.17	Nektar to Webcast Presentation at the Piper Jaffray 29th Annual Healthcare Conference in New York City (PR Newswire)
24.11.17	Nektar Therapeutics Turns Higher After Seeing Initial Weakness (RTTNews)
24.11.17	Bayer erleidet Rückschlag bei Studie zu Amikacin (Dow Jones) Die Bayer AG mit einem Kombinationsprodukt zur Behandlung von Lungenentzündung einen Rückschlag erlitten.» mehr
24.11.17	Bayer Says INHALE Did Not Demonstrate Superiority (RTTNews)
24.11.17	Phase III study with Amikacin Inhale in intubated and mechanically ventilated patients with Gram-negative pneumonia does not meet primary endpoint of superiority (PR Newswire)
22.11.17	Nektar Announces Key Executive Promotions to Drive the Continued Growth of the Company's Immuno-Oncology Pipeline (PR Newswire)
17.11.17	Are You Keeping An Eye On EARS And 6 Other Pharma Stocks? (RTTNews)
16.11.17	SGMO Emerges Champion, Mark Your Calendar For ANTH, No Stopping NKTR (RTTNews)
14.11.17	NKTR's Pivot Data Pleases Investors, OPHT Catches Eyes, CALA Craters, Wave Rises (RTTNews)
13.11.17	FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE (RTTNews)
11.11.17	First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative... (PR Newswire)
10.11.17	Nektar to Webcast Presentation at Jefferies 2017 London Healthcare Conference (PR Newswire)
08.11.17	XOMA Shines, PTGX Awaits Data, SELB Implodes, No Stopping NKTR (RTTNews)
07.11.17	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)
07.11.17	Nektar Therapeutics Reports Financial Results for the Third Quarter of 2017 (PR Newswire)
07.11.17	New Data Featuring Nektar Therapeutics' Wholly-Owned Immuno-Oncology Pipeline to be Presented at the 2017 Society for Immunotherapy of Cancer 32nd Annual Meeting (PR Newswire)
07.11.17	Nektar Therapeutics Presents Preclinical Data on NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 2017 American College of Rheumatology Annual Meeting (PR Newswire)
31.10.17	Nektar to Announce Financial Results for the Third Quarter of 2017 on Tuesday, November 7, 2017, After Close of U.S.-Based Financial Markets (PR Newswire)
21.09.17	Nektar Therapeutics Appoints Biotechnology Executive Jeff Ajer as New Board Member (PR Newswire)
20.09.17	DoorDash Expands Service In New York Metropolitan Area, Offering Door-To-Door Delivery From Top Local Restaurants (PR Newswire)
20.09.17	Nektar Therapeutics Announces Seven Abstracts Accepted for Presentation at 2017 Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting (PR Newswire)
12.09.17	Nektar Therapeutics Initiates PROPEL Clinical Study to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with TECENTRIQ® (atezolizumab) or KEYTRUDA® (pembrolizumab) (PR Newswire)
07.09.17	Nektar Therapeutics Presents Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at 2017 PAINWeek® (PR Newswire)
06.09.17	Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 2017 Morgan Stanley Global Healthcare Conference in New York City (PR Newswire)
30.08.17	Nektar Therapeutics to Present Clinical Data from Phase 3 SUMMIT-07 Study of NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain, at PAINWeek® (PR Newswire)
08.08.17	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
08.08.17	Nektar Therapeutics Reports Financial Results for the Second Quarter of 2017 (PR Newswire)
02.08.17	Nektar to Announce Financial Results for the Second Quarter of 2017 on Tuesday, August 8, 2017, After Close of U.S.-Based Financial Markets (PR Newswire)
24.07.17	MÄRKTE USA/Nasdaq-Indizes auf Allzeithoch - Quartalszahlen im Fokus (Dow Jones)
24.07.17	MÄRKTE USA/US-Wachstumsprognose des IWF bremst Wall Street (Dow Jones)
24.07.17	Eli Lilly Agrees With Nektar To Co-Develop NKTR - 358 (RTTNews)
24.07.17	Lilly and Nektar Therapeutics Announce Alliance to Develop and Commercialize NKTR-358, A Novel Autoimmune Therapy (PR Newswire)
19.07.17	FDA Nod For GILD, It's Take 2 For AEZS' Macrilen, VRTX Soars On CF Drug Trials (RTTNews)
18.07.17	Nektar Posts Positive Topline Data From Human Abuse Potential Study For NKTR-181 (RTTNews)
18.07.17	Nektar Announces Topline Data from Human Abuse Potential Study for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Pain (PR Newswire)
12.07.17	Gainers & Losers Of July 11: ARNA, FOLD, VSTM, TOCA, GTHX... (RTTNews)
10.07.17	Nektar Presents New Preclinical Data for NKTR-358, a First-in-Class Regulatory T Cell Stimulator, at 13th World Congress of Inflammation in London (PR Newswire)
07.07.17	Daily Technical Summary Reports on Biotech Stocks -- Juno Therapeutics, Lexicon Pharma, NantKwest, and Nektar Therapeutics (PR Newswire)
06.06.17	Nektar to Webcast Presentation at Jefferies 2017 Global Healthcare Conference in New York City (PR Newswire)
05.06.17	Nektar Presents New Clinical Data from Two Studies of NKTR-214, a CD122-Biased Agonist, at 2017 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
25.05.17	Biotech Stocks Under Scanner -- Juno Therapeutics, Nektar Therapeutics, Threshold Pharma, and Bellerophon Therapeutics (PR Newswire)
22.05.17	New Research Collaboration between Nektar and Takeda to Explore Combination Cancer Therapy Approaches with NKTR-214, a CD122-Biased Agonist, and Five Takeda Cancer Therapy Compounds (PR Newswire)
17.05.17	Nyansa Named 2017 "Cool Vendor" In Mobile And Wireless Analytics By Gartner (PR Newswire)
15.05.17	Nektar to Webcast Presentation at UBS Global Healthcare Conference 2017 in New York (PR Newswire)
11.05.17	Hennessy Advisors, Inc. to Acquire the Rainier U.S. Equity Funds (PR Newswire)
10.05.17	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
09.05.17	Nektar Therapeutics Reports Financial Results for the First Quarter of 2017 (PR Newswire)
03.05.17	Nektar Appoints Brian L. Kotzin, M.D. as Head of Clinical Development for Nektar's Immunology Program (PR Newswire)
20.04.17	Nektar Therapeutics to Host Analyst & Investor Event at 2017 ASCO Annual Meeting (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

04.12.24		Freundlicher Handel: NASDAQ Composite am Mittag im Plus
03.12.24		Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen
27.11.24		Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge
22.11.24		Börse New York: NASDAQ Composite stärker
22.11.24		Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
15.11.24		Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste
15.11.24		NASDAQ Composite aktuell: NASDAQ Composite mittags mit Abgaben

04.12.24

Freundlicher Handel: NASDAQ Composite am Mittag im Plus

03.12.24

Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen

27.11.24

Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge

22.11.24

Börse New York: NASDAQ Composite stärker

22.11.24

Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite

15.11.24

Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge

15.11.24

Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste

15.11.24

NASDAQ Composite aktuell: NASDAQ Composite mittags mit Abgaben

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Logitech Intl	74.04	2.41 %	K V
ABB	52.12	1.68 %	K V
Geberit	552.80	1.32 %	K V
Alcon	78.04	1.19 %	K V
CieFinRichemont	129.05	1.10 %	K V
Swiss Life Hldg	686.00	-0.64 %	K V
Zurich Insur Gr	555.20	-1.00 %	K V
Holcim	90.66	-1.31 %	K V
Kuehne+Nagel Int	210.60	-1.31 %	K V
Novartis	90.10	-3.14 %	K V

Nachrichten zu Nektar Therapeutics

Aktien Top/Flop

Nektar Therapeutics Peer Group Nachrichten

Meistgelesene Nachrichten